SEP 10, 2026 · PHASE 3 TRIAL
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL
ClinicalTrials.gov
This is a registered but not-yet-recruiting Phase 3 RCT with no results posted; the design is sound but conduct and outcomes remain unknown.
Reported
PhasePHASE3
Planned sample size398
Primary outcome measure28-day mortality